| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1042771660 |
| P356 | DOI | 10.1038/SJ.LEU.2403136 |
| P698 | PubMed publication ID | 14562124 |
| P5875 | ResearchGate publication ID | 9048596 |
| P50 | author | Peter Hokland | Q37830927 |
| Giuseppe Saglio | Q53342434 | ||
| Eric Delabesse | Q57287418 | ||
| Jacques Van Dongen | Q60655923 | ||
| P2093 | author name string | Dee R | |
| Bi W | |||
| van der Velden VH | |||
| Lion T | |||
| Watzinger F | |||
| Gottardi E | |||
| Pallisgaard N | |||
| Beillard E | |||
| Gabert J | |||
| Macintyre E | |||
| van der Schoot E | |||
| P2860 | cites work | Cyclophilin A, the Major Intracellular Receptor for the Immunosuppressant Cyclosporin A, Maps to Chromosome 7p11.2-p13: Four Pseudogenes Map to Chromosomes 3, 10, 14, and 18 | Q24314870 |
| Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays | Q28140044 | ||
| Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia | Q28212054 | ||
| Identification and analysis of over 2000 ribosomal protein pseudogenes in the human genome | Q28775742 | ||
| Current recommendations for positive controls in RT-PCR assays | Q34309821 | ||
| Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction | Q34321881 | ||
| X-chromosome inactivation and human genetic disease | Q35062073 | ||
| Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. | Q35561038 | ||
| Human glyceraldehyde-3-phosphate dehydrogenase pseudogenes: molecular evolution and a possible mechanism for amplification | Q35702854 | ||
| Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript | Q38319141 | ||
| Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR. | Q40821721 | ||
| Molecular analysis of transferrin receptor mRNA expression in acute myeloid leukaemia | Q43808451 | ||
| Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction | Q43901112 | ||
| Quantitative analysis of beta-actin, beta-2-microglobulin and porphobilinogen deaminase mRNA and their comparison as control transcripts for RT-PCR. | Q43989560 | ||
| Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group | Q47330036 | ||
| Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia | Q49279553 | ||
| Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. | Q50751273 | ||
| Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. | Q53349829 | ||
| Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. | Q55035685 | ||
| Mechanisms of differential transferrin receptor expression in normal hematopoiesis | Q57616766 | ||
| Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR | Q58455808 | ||
| BIOMED-1 concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings | Q61939586 | ||
| Human beta-actin retropseudogenes interfere with RT-PCR | Q71544442 | ||
| Debate round-table. Appropriate controls for RT-PCR | Q73401605 | ||
| Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR | Q73446193 | ||
| Normalizing complementary DNA by quantitative reverse transcriptase-polymerase chain reaction of beta2-microglobulin: molecular monitoring of minimal residual disease in acute promyelocytic leukemia | Q73887103 | ||
| Quantitative analysis of TEL/AML1 fusion transcripts by real-time RT-PCR assay in childhood acute lymphoblastic leukemia | Q74171306 | ||
| Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts | Q74213181 | ||
| Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia | Q74282286 | ||
| The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation | Q74459267 | ||
| Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay | Q77299371 | ||
| Identification and validation of endogenous reference genes for expression profiling of T helper cell differentiation by quantitative real-time RT-PCR | Q77299611 | ||
| Screening for core binding factor gene rearrangements in acute myeloid leukemia | Q78035259 | ||
| P433 | issue | 12 | |
| P921 | main subject | leukemia | Q29496 |
| diagnosis | Q16644043 | ||
| P304 | page(s) | 2474-2486 | |
| P577 | publication date | 2003-12-01 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program | |
| P478 | volume | 17 |
| Q58041694 | 14q deletions are associated with trisomy 12,NOTCH1mutations and unmutatedIGHVgenes in chronic lymphocytic leukemia and small lymphocytic lymphoma |
| Q35059443 | A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR |
| Q37334945 | A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib |
| Q35561034 | A further milestone towards comprehensive standardization of quantitative RT-PCR protocols for leukemic fusion gene transcripts has been reached |
| Q37623156 | A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms |
| Q41312327 | A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system |
| Q46099641 | A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia. |
| Q34655203 | A pan-cancer analysis of alternative splicing events reveals novel tumor-associated splice variants of matriptase. |
| Q42127851 | A pipeline with multiplex reverse transcription polymerase chain reaction and microarray for screening of chromosomal translocations in leukemia |
| Q33587624 | A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon α. |
| Q33822032 | A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. |
| Q46976753 | Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9. |
| Q36123315 | Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia. |
| Q38089228 | Advances in molecular diagnostics of myeloproliferative disorders |
| Q54336250 | Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. |
| Q54282566 | Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. |
| Q79235598 | Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study |
| Q49335168 | Amyloid precursor protein has clinical and prognostic significance in AML1-ETO-positive acute myeloid leukemia |
| Q42970294 | An In-House Method for Molecular Monitoring of BCR-ABL. |
| Q41978063 | An unusual case of high hyperdiploid childhood ALL with cryptic BCR/ABL1 rearrangement. |
| Q44586307 | Analysis of WT1 mutations, expression levels and single nucleotide polymorphism rs16754 in de novo non-M3 acute myeloid leukemia |
| Q38262877 | Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules. |
| Q90682089 | Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology |
| Q53215863 | Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia. |
| Q50670959 | Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3-Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferon-Positive Primary Sjögren's Syndrome. |
| Q42930500 | BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia |
| Q90012698 | BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia |
| Q54648205 | BCR-ABL1 transcript levels increase in peripheral blood but not in granulocytes after physical exercise in patients with chronic myeloid leukemia. |
| Q38852493 | BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene |
| Q60044320 | BRAF V600E mutation and 9p21: CDKN2A/B and MTAP co-deletions - Markers in the clinical stratification of pediatric gliomas |
| Q36884361 | Best Practices in Chronic Myeloid Leukemia Monitoring and Management |
| Q46686185 | Blockade of CD127 Exerts a Dichotomous Clinical Effect in Marmoset Experimental Autoimmune Encephalomyelitis. |
| Q42066221 | Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene |
| Q43119835 | Both SEPT2 and MLL are down-regulated in MLL-SEPT2 therapy-related myeloid neoplasia |
| Q54648219 | CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes. |
| Q51322003 | CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis. |
| Q42016116 | CCN3: a key growth regulator in Chronic Myeloid Leukaemia |
| Q28543785 | CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humans |
| Q33755327 | CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency |
| Q34656369 | CLL cells respond to B-Cell receptor stimulation with a microRNA/mRNA signature associated with MYC activation and cell cycle progression |
| Q48183562 | Can exome scans be expected to be part of real-time decision-making in patients with haematological cancers? |
| Q46215222 | Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients |
| Q54204813 | Cell sorting enables interphase fluorescence in situ hybridization detection of low BCR-ABL1 producing stem cells in chronic myeloid leukaemia patients beyond deep molecular remission. |
| Q40137810 | Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. |
| Q38044772 | Chromosomal aberrations and fusion genes in myeloid malignancies |
| Q34522810 | Chronic Myelogenous Leukemia, Version 1.2014 |
| Q36731265 | Chronic Myeloid Leukaemia in The 21st Century |
| Q45259659 | Chronic myeloid leukaemia with BCR-ABL fusion genes located to both chromosomes 9, cyclic leukocytosis and nodal T-lymphoblastic transformation--durable complete remission following imatinib therapy |
| Q35640320 | Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. |
| Q36337918 | Chronic myeloproliferative disorders: a tyrosine kinase tale. |
| Q35054717 | Clinical and biological predictors of outcome following relapse of CML post-allo-SCT |
| Q48121119 | Clinical features and prognostic impact of PRDM16 expression in adult acute myeloid leukemia |
| Q50546615 | Clinical value of assessing the response to imatinib monitored by interphase FISH and RQ-PCR for BCR-ABL in peripheral blood for long-term survival of chronic phase CML patients: results of the Niigata CML-multi-institutional co-operative clinical s |
| Q45423288 | Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity |
| Q54313466 | Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns. |
| Q36789440 | Comparison of an international scale method and a log reduction method for monitoring of early molecular response in chronic myeloid leukemia patients |
| Q40745969 | Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy |
| Q33236641 | Comparison of the latest commercial short and long oligonucleotide microarray technologies |
| Q33587563 | Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial |
| Q41465370 | Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force |
| Q39344876 | Control of human hematopoietic stem/progenitor cell migration by the extracellular matrix protein Slit3. |
| Q36793471 | Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions |
| Q53610644 | Critical methodological factors in diagnosing minimal residual disease in hematological malignancies using quantitative PCR. |
| Q38728499 | Curcumin potentiates the effect of chemotherapy against acute lymphoblastic leukemia cells via downregulation of NF-κB. |
| Q46510723 | Current diagnostic requirements in chronic myeloid leukemia |
| Q33829373 | Cysteine and glycine-rich protein 2 (CSRP2) transcript levels correlate with leukemia relapse and leukemia-free survival in adults with B-cell acute lymphoblastic leukemia and normal cytogenetics |
| Q50706067 | Cytosine arabinoside-metabolizing enzyme genes are underexpressed in children with MLL gene-rearranged acute lymphoblastic leukemia. |
| Q36384979 | DEK protein level is a biomarker of CD138positive normal and malignant plasma cells. |
| Q43729633 | DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification. |
| Q80559056 | DNA and RNA isolated from tissues processed by microwave-accelerated apparatus MFX-800-3 are suitable for subsequent PCR and Q-RT-PCR amplification |
| Q50567870 | DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. |
| Q49540898 | Decreased Invasion of Urothelial Carcinoma of the Bladder by Inhibition of Matrix-Metalloproteinase 7. |
| Q38322066 | Delineation and molecular characterization of acute myeloid leukemia patients with coduplication of FLT3 and MLL. |
| Q50925376 | Detection of BCR-ABL using one step reverse transcriptase- polymerase chain reaction and microchip electrophoresis. |
| Q89359928 | Development and evaluation of armored RNA-based standards for quantification of BCR-ABL1p210/p190 fusion gene transcripts |
| Q35225262 | Development and validation of a 3-Plex RT-qPCR assay for the simultaneous detection and quantitation of the three PML-RARa fusion transcripts in acute promyelocytic leukemia |
| Q54148021 | Development of a cost-effective 'duplexed' real-time PCR assay for minimal residual disease monitoring of chronic myeloid leukemia using locked nucleic acid probes. |
| Q35971837 | Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia |
| Q33873297 | Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet. |
| Q64067404 | Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials |
| Q51039328 | Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease--a study within the Europe Against Cancer Program. |
| Q24599447 | Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na |
| Q37418952 | Does HOXA9 Gene Expression in Egyptian Chronic Myelogenous Leukemia Patients Affect Disease Progression? A Retrospective Cohort Study |
| Q35724527 | Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia |
| Q56974816 | Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in t |
| Q28478542 | Dynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro data |
| Q36346086 | Dysregulated signaling, proliferation and apoptosis impact on the pathogenesis of TCRγδ+ T cell large granular lymphocyte leukemia. |
| Q51092405 | E2F3a gene expression has prognostic significance in childhood acute lymphoblastic leukemia. |
| Q36263943 | Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia. |
| Q44453492 | Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome |
| Q34377581 | Effect of dietary polyphenols on K562 leukemia cells: a Foodomics approach |
| Q87684859 | Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q54644462 | Efficient and easy detection of MLL-AF4, MLL-AF9 and MLL-ENL fusion gene transcripts by multiplex real-time quantitative RT-PCR in TaqMan and LightCycler. |
| Q50886809 | Efficient detection of leukemia-related fusion transcripts by multiplex PCR applied on a microelectronic platform. |
| Q42204730 | Enterovirus RNA in longitudinal blood samples and risk of islet autoimmunity in children with a high genetic risk of type 1 diabetes: the MIDIA study. |
| Q89591326 | Enzymatic-based cytometry, a sensitive single-cell cytometric method to assess BCR-ABL1 activity in CML |
| Q57041027 | Eprobe mediated RT-qPCR for the detection of leukemia-associated fusion genes |
| Q35664358 | Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR-ABL1 on the international reporting scale. |
| Q33307453 | Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer |
| Q51821011 | Evaluation of a novel multiplex RT-qPCR assay for the quantification of leukemia-associated BCR-ABL1 translocation. |
| Q81197686 | Evaluation of real-time quantitative PCR machines for the monitoring of fusion gene transcripts using the Europe against cancer protocol |
| Q43452634 | Evaluation of the Abelson gene as a control gene for real-time quantitative PCR in multiple myeloma |
| Q42793913 | Evaluation of the Cepheid GeneXpert BCR-ABL assay |
| Q37119922 | Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. |
| Q38920994 | Expression analysis of BECN1 in acute myeloid leukemia: association with distinct cytogenetic and molecular abnormalities |
| Q40426413 | Expression of DNA repair gene Ku80 in lymphoid neoplasm |
| Q52907170 | Expression of interleukin 15 in primary adult acute lymphoblastic leukemia. |
| Q51748028 | Expression of lineage markers using real-time quantitative polymerase chain reaction (RT-qPCR) in normal and in leukemia bone marrow. |
| Q35009176 | Expression patterns of microRNAs associated with CML phases and their disease related targets |
| Q42867431 | Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia |
| Q92310665 | External quality assessment for PML-RARα detection in acute promyelocytic leukemia: Findings and summary |
| Q79829828 | FOXP3 expression in peripheral blood rapidly recovers and lacks correlation with the occurrence of graft-versus-host disease after allogeneic stem cell transplantation |
| Q37285726 | FPGS rs1544105 polymorphism is associated with treatment outcome in pediatric B-cell precursor acute lymphoblastic leukemia |
| Q42012792 | Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients |
| Q24604850 | Flow cytometric immunobead assay for fast and easy detection of PML-RARA fusion proteins for the diagnosis of acute promyelocytic leukemia |
| Q34977308 | Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients. |
| Q33798318 | Fluorescent-magnetic-biotargeting multifunctional nanobioprobes for detecting and isolating multiple types of tumor cells |
| Q40402064 | Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients |
| Q34340727 | Fresh and cryopreserved, uncultured adipose tissue-derived stem and regenerative cells ameliorate ischemia–reperfusion-induced acute kidney injury |
| Q33862467 | From Blood to Lesioned Brain: An In Vitro Study on Migration Mechanisms of Human Nasal Olfactory Stem Cells. |
| Q80833954 | Gene expression profiling of minimal residual disease in acute myeloid leukaemia by novel multiplex-PCR-based method |
| Q40321847 | Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients |
| Q41498838 | Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance |
| Q64390415 | Genetic and epigenetic determinants mediate proneness of oncogene breakpoint sites for involvement in TCR translocations |
| Q33555627 | Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia |
| Q34427193 | Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X. |
| Q50996253 | Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study. |
| Q35990687 | Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia |
| Q35080710 | Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor |
| Q43971962 | Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia |
| Q28504757 | HEX expression and localization in normal mammary gland and breast carcinoma |
| Q41485317 | Haem arginate infusion stimulates haem oxygenase-1 expression in healthy subjects. |
| Q58023925 | Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories |
| Q49615274 | High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy. |
| Q41670609 | High IDH1 expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia |
| Q92567745 | High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia |
| Q41036515 | High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial |
| Q38301831 | High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML. |
| Q93228583 | Highly sensitive detection of SARS-CoV-2 RNA by multiplex rRT-PCR for molecular diagnosis of COVID-19 by clinical laboratories |
| Q54349191 | Housekeeping gene variability in the liver of alcoholic patients. |
| Q37545067 | How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet |
| Q37041919 | Human C/EBP-epsilon activator and repressor isoforms differentially reprogram myeloid lineage commitment and differentiation |
| Q28297413 | Human stanniocalcin-1 interacts with nuclear and cytoplasmic proteins and acts as a SUMO E3 ligase |
| Q39070526 | Hypoxia-related gene expression profile in childhood acute lymphoblastic leukemia: prognostic implications |
| Q50020484 | IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors. |
| Q82063965 | IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase |
| Q40173644 | Identification of leukemia-specific fusion gene transcripts with a novel oligonucleotide array |
| Q28386490 | Identification of reference genes across physiological states for qRT-PCR through microarray meta-analysis |
| Q28283017 | Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1 |
| Q41892319 | Imatinib mesylate resistance and mutations: An Indian experience |
| Q79520876 | Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis |
| Q51035595 | Immune modulation by a tolerogenic myelin oligodendrocyte glycoprotein (MOG)10-60 containing fusion protein in the marmoset experimental autoimmune encephalomyelitis model. |
| Q47967587 | Improvement of gene expression analysis by RQ-PCR technology: addition of BSA. |
| Q54389591 | In thyroid cancer cell lines expression of periostin gene is controlled by p73 and is not related to epigenetic marks of active transcription. |
| Q29614510 | Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders |
| Q54419664 | Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. |
| Q37308623 | Influence of late treatment on how chronic myeloid leukemia responds to imatinib |
| Q35900933 | Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells |
| Q28290118 | Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1 |
| Q86782294 | Intact expression status of RASSF1A in acute myeloid leukemia |
| Q40095759 | Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations |
| Q36096063 | Intragenic ERG Deletions Do Not Explain the Biology of ERG-Related Acute Lymphoblastic Leukemia. |
| Q49076752 | Kolmogorov-Smirnov statistical test for analysis of ZAP-70 expression in B-CLL, compared with quantitative PCR and IgV(H) mutation status. |
| Q35082503 | LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome. |
| Q54117334 | Laboratory Monitoring of Chronic Myeloid Leukemia in Patients on Tyrosine Kinase Inhibitors. |
| Q35603605 | Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. |
| Q37555303 | Lack of common TCRA and TCRB clonotypes in CD8(+)/TCRαβ(+) T-cell large granular lymphocyte leukemia: a review on the role of antigenic selection in the immunopathogenesis of CD8(+) T-LGL |
| Q36384606 | Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. |
| Q35220109 | Lipoprotein lipase SNPs rs13702 and rs301 correlate with clinical outcome in chronic lymphocytic leukemia patients. |
| Q33829079 | Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients |
| Q64119737 | Long-term molecular remission in a patient with acute myeloid leukemia harboring a new NUP98-LEDGF rearrangement |
| Q48219436 | Low CREBBP expression is associated with adverse long-term outcomes in paediatric acute lymphoblastic leukaemia |
| Q80113979 | Low MCL-1 mRNA expression correlates with prolonged survival in B-cell chronic lymphocytic leukemia |
| Q36919799 | Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation |
| Q54541357 | Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. |
| Q34155213 | Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended |
| Q52992928 | Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices. |
| Q47862030 | Methods of Detection of Measurable Residual Disease in AML. |
| Q33597549 | Methylation pattern of preferentially expressed antigen of melanoma in acute myeloid leukemia and myelodysplastic syndromes |
| Q52655669 | MiR-362-5p as a novel prognostic predictor of cytogenetically normal acute myeloid leukemia. |
| Q36707753 | Mimicking the tumour microenvironment of chronic lymphocytic leukaemia in vitro critically depends on the type of B-cell receptor stimulation. |
| Q36344100 | Miniaturization applied to analysis of nucleic acids in heterogeneous tissues |
| Q54163933 | Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma. |
| Q26828511 | Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies |
| Q38791735 | Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia |
| Q38494659 | Minimal residual disease in acute myeloid leukemia--current status and future perspectives |
| Q43175202 | Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement |
| Q48125822 | Minimal residual disease monitoring in childhood B lymphoblastic leukemia with t(12;21)(p13;q22); ETV6-RUNX1: concordant results using quantitation of fusion transcript and flow cytometry |
| Q38220970 | Minimal residual disease testing in hematologic malignancies and solid cancer |
| Q47734674 | Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party. |
| Q51829353 | Molecular Detection of BCR-ABL in Chronic Myeloid Leukemia. |
| Q36816685 | Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia |
| Q92188325 | Molecular Monitoring in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with the Variant e13a3 BCR-ABL1 Fusion |
| Q34561626 | Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH). |
| Q53588817 | Molecular characterization and follow-up of five CML patients with new BCR-ABL1 fusion transcripts. |
| Q37542270 | Molecular diagnosis of myeloproliferative neoplasms |
| Q38481945 | Molecular genetic evaluation of myeloproliferative neoplasms |
| Q38176284 | Molecular monitoring |
| Q46416550 | Molecular monitoring in NUP214-ABL-positive T-acute lymphoblastic leukemia reveals clonal diversity and helps to guide targeted therapy. |
| Q43082879 | Molecular monitoring in patients with chronic myelogenous leukemia |
| Q35790163 | Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts. |
| Q38392702 | Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization |
| Q41768874 | Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis |
| Q53640330 | Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion. |
| Q37696776 | Molecular techniques for the personalised management of patients with chronic myeloid leukaemia |
| Q54631835 | Molecular typing of adult acute myeloid leukaemia: significance of translocations, tandem duplications, methylation, and selective gene expression profiling. |
| Q35849776 | Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results |
| Q36599984 | Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management |
| Q89455205 | Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia |
| Q46668662 | Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. |
| Q36652555 | Monitoring of minimal residual disease in leukemia, advantages and pitfalls |
| Q54203721 | Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia. |
| Q33659118 | MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome. |
| Q28749228 | NPM1 deletion is associated with gross chromosomal rearrangements in leukemia |
| Q54362611 | NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression. |
| Q55040098 | NUP214-ABL1 amplification in t(5;14)/HOX11L2-positive ALL present with several forms and may have a prognostic significance. |
| Q40567402 | New Quantitative Method to Identify NPM1 Mutations in Acute Myeloid Leukaemia |
| Q39981524 | New cellular markers at diagnosis are associated with isolated central nervous system relapse in paediatric B-cell precursor acute lymphoblastic leukaemia |
| Q43214271 | OGG1 is a novel prognostic indicator in acute myeloid leukaemia |
| Q33781178 | Olfactory stem cells, a new cellular model for studying molecular mechanisms underlying familial dysautonomia |
| Q33956085 | Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation |
| Q40330608 | P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors |
| Q35955221 | PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia |
| Q35576881 | PINCH-2 expression in cancers involving serosal effusions using quantitative PCR. |
| Q64926609 | PPIA, HPRT1, and YWHAZ Genes Are Suitable for Normalization of mRNA Expression in Long-Term Expanded Human Mesenchymal Stem Cells. |
| Q42623661 | PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies |
| Q53017093 | PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase. |
| Q92741400 | Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay |
| Q54613497 | Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia. |
| Q41715958 | Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT. |
| Q48159027 | Presence of HLA-DR Molecules and HLA-DRB1 mRNA in Circulating CD4(+) T Cells. |
| Q38762631 | Present and future of molecular monitoring in chronic myeloid leukaemia |
| Q36059184 | Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome |
| Q36745815 | Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression |
| Q42738559 | Prognostic Significance of the Lymphoblastic Leukemia-Derived Sequence 1 (LYL1) GeneExpression in Egyptian Patients with AcuteMyeloid Leukemia |
| Q35986474 | Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia |
| Q33886181 | Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia |
| Q37148110 | Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia |
| Q51151301 | Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry. |
| Q61053580 | Prospective multicentric molecular study for poor prognosis fusion transcripts at diagnosis in adult B-lineage ALL patients: the LALA 94 experience |
| Q37696313 | Protocol for qRT-PCR analysis from formalin fixed paraffin embedded tissue sections from diffuse large b-cell lymphoma: Validation of the six-gene predictor score. |
| Q35887790 | Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells |
| Q36817650 | Quality control methods for optimal BCR-ABL1 clinical testing in human whole blood samples |
| Q37727668 | Quality of life in chronic myeloid leukaemia patients after haematopoietic cell transplantation pretreated with second-generation tyrosine kinase inhibitors |
| Q42720643 | Quantification of PML/RARa transcript after induction predicts outcome in children with acute promyelocytic leukemia |
| Q80313420 | Quantitative RT-PCR analysis of sphingolipid metabolic enzymes in acute leukemia and myelodysplastic syndromes |
| Q30492706 | Quantitative TaqMan real-time PCR assays for gene expression normalisation in feline tissues |
| Q82758876 | Quantitative detection of BCR-ABL fusion gene and its application in monitoring chronic myeloid leukemia treatment |
| Q98772371 | Quantitative monitoring of minimal residual disease in childhood acute lymphoblastic leukemia using TEL-AML1 fusion transcript as a marker |
| Q38340772 | Quantitative monitoring of single nucleotide mutations by allele-specific quantitative PCR can be used for the assessment of minimal residual disease in patients with hematological malignancies throughout their clinical course |
| Q54516478 | RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation. |
| Q52569573 | RETRACTED: Arsenic trioxide inhibits proliferation and induced apoptosis of leukemia stem cells with drug resistance. |
| Q33748792 | RNA quantification using gold nanoprobes - application to cancer diagnostics |
| Q34998533 | RNA-Seq reveals spliceosome and proteasome genes as most consistent transcripts in human cancer cells |
| Q44052187 | Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma |
| Q36600934 | Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia |
| Q45405674 | Readying the minimal residual disease concept in acute myeloid leukaemia for prime time - the American way. |
| Q54318403 | Real-time PCR quantification of major Wilms' tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences. |
| Q34861985 | Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation |
| Q37220846 | Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis |
| Q51888520 | Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. |
| Q34612637 | Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. |
| Q54506763 | Reply to 'What do we mean by sensitivity when we talk about detecting minimal residual disease?' by Steinbach and Debatin. |
| Q48372855 | Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7). |
| Q80468804 | Retrospective comparison of qualitative and quantitative reverse transcriptase polymerase chain reaction in diagnosing and monitoring the ALL1-AF4 fusion transcript in patients with acute lymphoblastic leukaemia |
| Q47290500 | Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations. |
| Q41571058 | Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL. |
| Q51016169 | SETBP1 mutation analysis in 944 patients with MDS and AML. |
| Q38022075 | Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation |
| Q45173736 | Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate |
| Q28552969 | Sphingosine-1-Phosphate Induces Dose-Dependent Chemotaxis or Fugetaxis of T-ALL Blasts through S1P1 Activation |
| Q92284305 | Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 |
| Q35561038 | Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. |
| Q39992358 | Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. |
| Q37662200 | Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. |
| Q38002704 | Standardized definitions of molecular response in chronic myeloid leukemia. |
| Q46735722 | Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products |
| Q46730765 | Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia |
| Q51743495 | Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. |
| Q39968040 | Systemic increase in type I interferon activity in Sjögren's syndrome: a putative role for plasmacytoid dendritic cells |
| Q54335310 | Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia. |
| Q34707452 | T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy |
| Q33765598 | T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus? |
| Q51705397 | TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner. |
| Q59342678 | Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia |
| Q96292691 | Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System |
| Q92234747 | Targeting miR-193a-AML1-ETO-β-catenin axis by melatonin suppresses the self-renewal of leukaemia stem cells in leukaemia with t (8;21) translocation |
| Q33899947 | Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome |
| Q24649948 | Tenascin-X is a novel diagnostic marker of malignant mesothelioma |
| Q55401060 | The Association between PARP1 and LIG3 Expression Levels and Chromosomal Translocations in Acute Myeloid Leukemia Patients. |
| Q42479929 | The Chemorepellent Slit3 Promotes Monocyte Migration |
| Q47159993 | The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability |
| Q44606506 | The ETV6/RUNX1 fusion transcript is not detected in RNA isolated from neonatal dried blood spots from children later diagnosed with the corresponding leukemia |
| Q46931482 | The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype |
| Q43006867 | The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population |
| Q38665455 | The clinical significance of monitoring the expression of the SIL-TAL1 fusion gene in T-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. |
| Q37580157 | The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma. |
| Q35717741 | The composition of the mesenchymal stromal cell compartment in human bone marrow changes during development and aging |
| Q37628021 | The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia |
| Q41553306 | The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients |
| Q84773086 | The role of TFPI in regulation of TF-induced thrombogenicity on the surface of human monocytes |
| Q37924989 | The role of molecular genetic analysis within the diagnostic haemato-oncology laboratory |
| Q48151269 | The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias |
| Q45000807 | The use of housekeeping genes for real-time PCR-based quantification of fusion gene transcripts in acute myeloid leukemia |
| Q54489238 | Three-way translocation (X;20;16)(p11;q13;q23) in essential thrombocythemia implicates NFATC2 in dysregulation of CSF2 expression and megakaryocyte proliferation. |
| Q52919448 | Thymic adult T-cell acute lymphoblastic leukemia stratified in standard- and high-risk group by aberrant HOX11L2 expression: experience of the German multicenter ALL study group. |
| Q44517995 | Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents |
| Q35665925 | Type 2 Diabetes Monocyte MicroRNA and mRNA Expression: Dyslipidemia Associates with Increased Differentiation-Related Genes but Not Inflammatory Activation |
| Q49299269 | Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors? |
| Q44890063 | Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia |
| Q51904566 | Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer. |
| Q40404105 | Validation of a digital PCR method for quantification of DNA copy number concentrations by using a certified reference material |
| Q46917660 | Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells |
| Q47594181 | WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study |
| Q36736174 | Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? |
| Q40035267 | Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia |
| Q54627391 | Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. |
| Q54367385 | Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. |
| Q83587561 | [Linear B-cell epitope prediction] |
| Q50737622 | [Prognostic value of dynamic monitoring of RUNX1-RUNX1T1 transcript in pediatric acute myeloid leukemia]. |
| Q89454891 | [Significance of BCR-ABL fusion gene detection in CD34 (+) cells of chronic myelogenous leukemia patients] |
| Q42793682 | beta-Glucuronidase is an optimal normalization control gene for molecular monitoring of chronic myelogenous leukemia |
| Q44222759 | hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia |
| Q35632171 | miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level |
| Q92566885 | miR-362-5p promotes cell proliferation and cell cycle progression by targeting GAS7 in acute myeloid leukemia |
Search more.